Compare PGEN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | DCTH |
|---|---|---|
| Founded | 1998 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 350.7M |
| IPO Year | N/A | N/A |
| Metric | PGEN | DCTH |
|---|---|---|
| Price | $4.43 | $10.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.67 | ★ $22.60 |
| AVG Volume (30 Days) | ★ 3.9M | 716.2K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $6,309,000.00 | ★ $79,603,000.00 |
| Revenue This Year | $342.78 | $131.97 |
| Revenue Next Year | $478.46 | $38.84 |
| P/E Ratio | ★ N/A | $287.78 |
| Revenue Growth | 59.20 | ★ 251.54 |
| 52 Week Low | $0.67 | $8.12 |
| 52 Week High | $5.23 | $18.23 |
| Indicator | PGEN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 55.89 |
| Support Level | $3.64 | $9.84 |
| Resistance Level | $3.75 | $10.28 |
| Average True Range (ATR) | 0.26 | 0.45 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 84.62 | 57.50 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.